Translate page

Collage Hochhaus Ong Kopie


Professor Andreas Hochhaus
Director of the Department of Hematology and Medical Oncology
Jena University Hospital (Germany)

Professor Tiong S Ong
Duke-NUS Medical School (Singapore) &
Duke University Medical Center, NC (USA) 

Overview of selected oral presentations during the meeting:

Clinical highlights:

  • Balancing tolerability and efficacy goals of patients and physicians through shared treatment decision-making
  • Selectivity of kinase inhibitors
  • ASCEMBL study results
  • Asciminib resistance mutations (from published studies)
  • Combination therapy of asciminib and ponatinib was effective in the treatment of blast phase CML CDX model
  • Rough guide to 3L+ therapies
  • TIGER study results
  • FASCINATION German CML XI study results
  • Prognostic factors for 3-year MMR maintenance in CML patients in the EURO-SKI trial

Biological highlights:

  • Current areas of translational research interest in chronic myeloid leukemia
  • Combination of large spleen size and low in vivo kinase inhibition in an early predictor of inferior molecular response for patients with CML
  • What can we learn from single cell studies in chronic myeloid leukemia?
  • Drug profiling for CML blast crisis
  • Identification of novel factors controlling non genetic cell plasticity in chronic myeloid leukemia
  • Mechanisms of trombogenesis in patients with chronic myeloid leukemia under treatment with ponatinib and other TKIs
  • Timing and clonal trajectory to chronic myeloid leukemia driven by the Philadelphia chromosome

Q&A Session

If you have any questions or comments to the speakers, please email